Interdependent biological systems, multi-functional molecules: The evolving role of tissue factor pathway inhibitor beyond anti-coagulation

Thrombosis Research

Volumn 125, Issue SUPPL. 1, 2010, Pages

  Holroyd, Eric W ^a   Simari, Robert D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Atherosclerosis; Inflammation; Lipid metabolism; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANGIOGENESIS; ANTICOAGULATION; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIPID METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ALGORITHMS; ATHEROSCLEROSIS; BLOOD COAGULATION; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LIPIDS; LIPOPROTEINS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; THROMBOPLASTIN;

EID: 77949264918     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.039     Document Type: Review

References (42)

1. Davidson C.J., Tuddenham E.G., and McVey J.H. 450 million years of hemostasis. J Thromb Haemost 1 7 (2003 Jul) 1487-1494
2. Broze G., Warren L., Novotny W., Higuchi D., Girard J., and Miletich J. The lipoprotein-associated coagulation inhibitor that inhibits factor Xa: insight into its possible mechanism of action. Blood 71 (1988) 335-343
3. Girard T., Warren L., Novotny W., Likert K., Brown S., and Miletich J. G.J. Broze J. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338 (1989) 518-520
4. Vincent J.L. Infection/inflammation and hemostasis. Curr Hematol Rep 2 5 (2003 Sep) 407-410
5. Schoenmakers S.H., Reitsma P.H., and Spek C.A. Blood coagulation factors as inflammatory mediators. Blood Cells Mol Dis 34 1 (Jan-Feb 2005) 30-37
6. Drake T.A., Morrissey J.H., and Edgington T.S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134 5 (May 1989) 1087-1097
7. Rivers R.P., Hathaway W.E., and Weston W.L. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 30 3 (1975 Jul) 311-316
8. Prydz H., Allison A.C., and Schorlemmer H.U. Further link between complement activation and blood coagulation. Nature 270 5633 (1977 Nov 10) 173-174
9. Versteeg H.H., Peppelenbosch M.P., and Spek C.A. The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?. Thromb Haemost 86 6 (2001 Dec) 1353-1359
10. Ruf W., Dorfleutner A., and Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost 1 7 (2003 Jul) 1495-1503
11. Pawlinski R., Pedersen B., Schabbauer G., Tencati M., Holscher T., Boisvert W., et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 103 4 (2004 Feb 15) 1342-1347
12. Taylor Jr. F.B., Chang A., Ruf W., Morrissey J.H., Hinshaw L., Catlett R., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33 3 (Mar 1991) 127-134
13. Opal S.M., Palardy J.E., Parejo N.A., and Creasey A.A. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 29 1 (2001 Jan) 13-17
14. Carr C., Bild G.S., Chang A.C., Peer G.T., Palmier M.O., Frazier R.B., et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 44 3 (Nov 1994) 126-137
15. Abraham E., Reinhart K., Opal S., Demeyer I., Doig C., Rodriguez A.L., et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290 2 (2003 Jul 9) 238-247
16. Ohkura N., Enjyoji K.-I., Kamikubo Y.-I., and Kato H. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 90 (1997) 1883-1892
17. Schirm S., Liu X., Jennings L.L., Jedrzejewski P., Dai Y., and Hardy S. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 199 12 (2009 Jun 15) 1807-1815
18. Ruf W., Fischer E.G., Huang H.Y., Miyagi Y., Ott I., Riewald M., et al. Diverse functions of protease receptor tissue factor in inflammation and metastasis. Immunol Res 21 2-3 (2000) 289-292
19. Mueller B., and Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 101 (1998) 1372-1378
20. Contrino J., Hair G., Kreutzer D., and Rickles F. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 2 (1996) 209-215
21. Uusitalo-Jarvinen H., Kurokawa T., Mueller B.M., Andrade-Gordon P., Friedlander M., and Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol 27 6 (2007 Jun) 1456-1462
22. Versteeg H.H., Schaffner F., Kerver M., Petersen H.H., Ahamed J., Felding-Habermann B., et al. Inhibition of tissue factor signaling suppresses tumor growth. Blood 111 1 (2008 Jan 1) 190-199
23. Belting M., Dorrell M.I., Sandgren S., Aguilar E., Ahamed J., Dorfleutner A., et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10 5 (2004 May) 502-509
24. Ahamed J., Belting M., and Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 105 6 (Mar 15 2005) 2384-2391
25. Hembrough T.A., Swartz G.M., Papathanassiu A., Vlasuk G.P., Rote W.E., Green S.J., et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 63 11 (2003 Jun 1) 2997-3000
26. Hembrough T.A., Ruiz J.F., Papathanassiu A.E., Green S.J., and Strickland D.K. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 276 (2001) 12241-12248
27. Hembrough T.A., Ruiz J.F., Swerdlow B.M., Swartz G.M., Hammers H.J., Zhang L., et al. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 103 9 (May 1 2004) 3374-3380 2004
28. Bajaj M.S., Birktoft J.J., Steer S.A., and Bajaj S.P. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86 4 (2001 Oct) 959-972
29. Provencal M., Michaud M., Beaulieu E., Ratel D., Rivard G.E., Gingras D., et al. Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost 99 3 (2008 Mar) 576-585
30. Channon K.M. The Endothelium and the Pathogenesis of Atherosclerosis. Medicine 30 4 (2002) 54-58
31. Moreno P.R., Purushothaman K.R., Fuster V., Echeverri D., Truszczynska H., Sharma S.K., et al. Plaque neovascularization is increased in ruptured therosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 110 14 (2004 Oct 5) 2032-2038
32. Wun T.C., Kretzmer K.K., Girard T.J., Miletich J.P., and Broze Jr. G.J. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263 13 (1988 May 5) 6001-6004
33. Novotny W., Girard T., Miletich J., and Broze Jr. G. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264 (1989) 18832-18837
34. Warshawsky I., GJ Broze J., and Schwartz A. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 91 (1994) 6664-6668
35. Narita M., Bu G., Olins G., Higuchi D., and Herz J. GJ Broze J, Schwartz A. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 270 42 (1995) 24800-24804
36. Horie S., Hiraishi S., Hamuro T., Kamikubo Y., and Matsuda J. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost 87 1 (2002 Jan) 80-85
37. Ohkura N., Hiraishi S., Itabe H., Hamuro T., Kamikubo Y., Takano T., et al. Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region. Antioxid Redox Signal 6 4 (2004 Aug) 705-712
38. Singh R., Pan S., Mueske C.S., Witt T., Kleppe L.S., Peterson T.E., et al. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res 89 1 (2001 Jul 6) 71-76
39. Pan S., Kleppe L.S., Witt T.A., Mueske C.S., and Simari R.D. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost 92 3 (2004 Sep) 495-502
40. Westrick R.J., Bodary P.F., Xu Z., Shen Y.C., Broze G.J., and Eitzman D.T. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice. Circulation 103 25 (2001 Jun 26) 3044-3046
41. Singh R., Pan S., Mueske C.S., Witt T.A., Kleppe L.S., Peterson T.E., et al. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodeling. Thromb Haemost 89 (2003) 747-751
42. Pan S., White T.A., Witt T.A., Chiriac A., Mueske C.S., and Simari R.D. Vascular-directed tissue factor pathway inhibitor overexpression regulates plasma cholesterol and reduces atherosclerotic plaque development. Circ Res 105 7 (Sep 25 2009) 713-720 8 p following 20